Clinical Trial Update: Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial updates on maraviroc for patients undergoing non-myeloablative allogeneic stem-cell transplantation (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-17